168 related articles for article (PubMed ID: 34097243)
1. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
[TBL] [Abstract][Full Text] [Related]
2. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
3. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
Jew S; Chang T; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Spektor TM; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Berenson JR
Br J Haematol; 2021 Jan; 192(2):272-280. PubMed ID: 32441777
[TBL] [Abstract][Full Text] [Related]
4. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Bujarski S; Sutanto C; Spektor TM; To J; Swift RA; Green T; Eades BR; Emamy-Sadr M; Souther E; Berenson JR
Hematol Oncol; 2022 Apr; 40(2):243-248. PubMed ID: 34982491
[TBL] [Abstract][Full Text] [Related]
5. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
[No Abstract] [Full Text] [Related]
6. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.
Visram A; Soof C; Rajkumar SV; Kumar SK; Bujarski S; Spektor TM; Kyle RA; Berenson JR; Dispenzieri A
Blood Cancer J; 2021 Jun; 11(6):120. PubMed ID: 34168119
[TBL] [Abstract][Full Text] [Related]
7. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
[TBL] [Abstract][Full Text] [Related]
8. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients.
Jew S; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Spektor TM; Berenson JR
Br J Haematol; 2021 Mar; 192(6):1064-1067. PubMed ID: 32321191
[TBL] [Abstract][Full Text] [Related]
9. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.
Soof CM; Spektor TM; Parikh SA; Slager SL; Rabe KG; Call TG; Kenderian SS; Ding W; Muchtar E; Ghermezi M; Kay NE; Berenson JR
Exp Hematol; 2022 Jul; 111():32-40. PubMed ID: 35525334
[TBL] [Abstract][Full Text] [Related]
10. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.
He SL; Cheng YH; Wang D; Xu ML; Que YM; Xu YJ; Ma LM; Li CR; Zhou JF
Curr Med Sci; 2021 Jun; 41(3):474-481. PubMed ID: 34169427
[TBL] [Abstract][Full Text] [Related]
11. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
[TBL] [Abstract][Full Text] [Related]
12. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma.
Alomari M; Kunacheewa C; Manasanch EE
Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
Guo P; Wang Y; He H; Chen D; Liu J; Qiang W; Lu J; Liang Y; Du J
Clin Exp Immunol; 2024 May; ():. PubMed ID: 38743453
[TBL] [Abstract][Full Text] [Related]
14. [Expression of sBCMA in Newly Diagnosed Multiple Myeloma Patients and Its Relationship with Prognosis].
Zheng LL; Li B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1108-1112. PubMed ID: 37551484
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients.
Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF
Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.
Jew S; Bujarski S; Regidor B; Emamy-Sadr M; Swift R; Eades B; Kim S; Eshaghian S; Berenson JR
Target Oncol; 2023 Sep; 18(5):735-747. PubMed ID: 37682503
[TBL] [Abstract][Full Text] [Related]
17. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.
Maglione PJ; Ko HM; Tokuyama M; Gyimesi G; Soof C; Li M; Sanchez E; Chen H; Radigan L; Berenson J; Cunningham-Rundles C
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):283-291.e1. PubMed ID: 31430592
[TBL] [Abstract][Full Text] [Related]
18. Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.
Udd KA; Bujarski S; Wirtschafter E; Spektor TM; Ghermezi M; Rassenti LZ; David ME; Nosrati JD; Rahbari AA; Wang J; Vardanyan S; Harutyunyan NM; Linesch J; Li M; Sanchez E; Chen H; Kipps TJ; Berenson JR
Target Oncol; 2019 Oct; 14(5):551-561. PubMed ID: 31473933
[TBL] [Abstract][Full Text] [Related]
19. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
[TBL] [Abstract][Full Text] [Related]
20. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]